Latest News | Cipla's Pithampur Unit Gets 8 Observations from USFDA After Inspection
Get latest articles and stories on Latest News at LatestLY. Drug major Cipla on Saturday said the US health regulator has issued Form 483 with eight observations after inspecting its Pithampur-based manufacturing facility in Madhya Pradesh.
New Delhi, Feb 18 (PTI) Drug major Cipla on Saturday said the US health regulator has issued Form 483 with eight observations after inspecting its Pithampur-based manufacturing facility in Madhya Pradesh.
The US Food and Drug Administration (USFDA) conducted a current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from February 6 - 17, the Mumbai-based drug firm said in a regulatory filing.
On conclusion of the inspection, the company has received 8 inspectional observations in Form 483, it added.
The company will work closely with the USFDA and is committed to address these comprehensively within stipulated time, it said.
Also Read | Tamil Nadu: Six Fishermen Attacked, Robbed by Unidentified Men in Midsea Near Point Calimere.
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)